MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review

Simple item page
dc.contributor.authorSingh, Priyanka
dc.date.accessioned2024-01-16T14:23:29Z
dc.date.accessioned2024-08-13T10:34:21Z
dc.date.available2024-01-16T14:23:29Z
dc.date.available2024-08-13T10:34:21Z
dc.date.issued2023-09-15T00:00:00
dc.description.abstractChronic myeloid leukemia (CML) is characterized by presence of Philadelphia chromosome, which harbors BCR-ABL oncogene responsible for encoding BCR-ABL oncoprotein. This oncoprotein interferes with cellular signaling pathways, resulting in tumor progression. Among these pathways, PI3K/Akt/mTOR pathway is significantly upregulated in CML. Tyrosine kinase inhibitors (TKIs) are current standard therapy for CML, and they have shown remarkable efficacy. However, emergence of TKIs drug resistance has necessitated investigation of novel therapeutic approaches. Components of PI3K/Akt/mTOR pathway have emerged as attractive targets in this context, as this pathway is known to be activated in TKIs-resistant CML cells/patients. Inhibiting this pathway may provide a complementary approach to improving TKIs� efficacy and treatment outcomes. Given previous research indicating that miRNAs play an inhibitory role in cancer, current study used computational tools to identify miRNAs that specifically target pathway�s core components. A comprehensive analysis was performed, resulting in identification of 111 miRNAs that potentially target PI3K/Akt/mTOR pathway. From this extensive list, 7 miRNAs was selected for further investigation based on their consistent downregulation across leukemia subtypes. Except for hsa-miR-199a-3p, remaining six miRNAs have been extensively studied in acute myeloid leukemia (AML). Given high similarity between AML and CML, it is believed that six miRNAs which are not studied in context of CML may also be advantageous for curing chemoresistance in CML. Building upon this knowledge, it is reasonable to speculate that a combination therapy approach involving use of miRNAs alongside TKIs may offer improved therapy for TKIs-resistant CML compared to TKIs monotherapy alone. � 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.en_US
dc.identifier.doi10.1007/s12032-023-02161-z
dc.identifier.issn13570560
dc.identifier.urihttps://doi.org/10.1007/s12032-023-02161-z
dc.identifier.urihttp://10.2.3.109/handle/32116/2948
dc.language.isoen_USen_US
dc.publisherSpringeren_US
dc.subjectBCR-ABL oncoproteinen_US
dc.subjectdbDEMCen_US
dc.subjectLeukemiaen_US
dc.subjectmiRBaseen_US
dc.subjectTargetScanen_US
dc.titleMicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a reviewen_US
dc.title.journalMedical Oncologyen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Biochemistry And Microbial Sciences - Research Publications